The effects of a digital health intervention on patient activation in chronic kidney disease
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the...
Disease
5 health technology start-ups finalists in global heart disease solution competition
DALLAS, Nov. 8, 2024 – High blood pressure, obesity and other risk factors contribute to high rates of heart disease...
Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease
Management of chronic kidney disease among patients with type 2 diabetes has undergone significant change in the last decade. Once...
Kidney disease and reproductive health
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the...
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
Will Herrington, MA, MBBS, MD, FRCP, FERACredit: Oxford UniversityPost-trial follow-up (PTFU) of the EMPA-KIDNEY trial has revealed that empagliflozin continues...
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
World Health Organization. Obesity and overweight. (2024).Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to...
